HSD17B10

3-hydroxyacyl-CoA dehydrogenase type-2 · Q99714 · HSD17B10 on Sugi Atlas →

2,798,454 patent compounds predicted against HSD17B10, 1,557,364 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Triclofenol (SCHEMBL1338)	1.00	11/20
Prednisone (SCHEMBL3288)	1.00	10/20
Cortisone (SCHEMBL4888)	1.00	10/20
Cortisone (SCHEMBL4502)	0.94	10/20
Aspirin (SCHEMBL1353)	1.00	9/20
Pentachlorophenol (SCHEMBL1492)	1.00	9/20
Prednisolone (SCHEMBL3233)	1.00	8/20
Prednisolone (SCHEMBL3234)	1.00	8/20
SCHEMBL4015	0.73	8/20
Methacycline (SCHEMBL4014)	0.70	8/20
Methacycline (SCHEMBL4016)	0.70	8/20
SCHEMBL3446	0.62	8/20
Cloprednol (SCHEMBL4886)	0.61	8/20
Meclocycline (SCHEMBL3445)	0.59	8/20
SCHEMBL4546	0.57	8/20
Cephalexin Anhydrous (SCHEMBL2961)	1.00	7/20
Esculin (SCHEMBL2893)	1.00	6/20
Esculin (SCHEMBL2894)	1.00	6/20
Cephradine (SCHEMBL3244)	1.00	6/20
Epinephrine (SCHEMBL3814)	1.00	6/20

Clinical trials — most relevant to HSD17B10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)	PHASE3	COMPLETED
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy	PHASE3	COMPLETED
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris	PHASE1/PHASE2	UNKNOWN
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency	nan	UNKNOWN
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
Androgens and NAFLD Longitudinal Cohort Study	nan	RECRUITING
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Linear Growth of Children With Congenital Adrenal Hyperplasia	nan	UNKNOWN
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Final Height in Patients With CAH	nan	UNKNOWN
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas	nan	UNKNOWN
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers	nan	UNKNOWN
Study of Protein Translocation in Patients With Beta-Oxidation Disorders	nan	COMPLETED
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH	nan	COMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Study of Smith-Lemli-Opitz Syndrome	nan	COMPLETED
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Gut Microbiome in Patients With Polycystic Ovary Syndrome	nan	UNKNOWN
Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)	nan	COMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Hepatic Lipid Metabolism-Alcohol Use Disorder	nan	RECRUITING
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a HSD17B10 binder may also engage these)

Protein	Name	Similarity
O08756	—	1.000	O08756 →
O70351	—	0.998	O70351 →
O02691	—	0.998	O02691 →
O18404	—	0.986	O18404 →
Q5RCF8	—	0.983	Q5RCF8 →
P9WES5	—	0.982	P9WES5 →
A0A3G9HAL8	—	0.981	A0A3G9HAL8 →
O93868	—	0.980	O93868 →
Q9BTZ2	—	0.979	Q9BTZ2 →
P0DKI3	—	0.978	P0DKI3 →
A3F5F0	—	0.978	A3F5F0 →
F4J300	—	0.977	F4J300 →
Q99LB2	—	0.977	Q99LB2 →
A0A2H3D8Y2	—	0.977	A0A2H3D8Y2 →
A0A8F5SIS3	—	0.977	A0A8F5SIS3 →
A0A165U5V5	—	0.976	A0A165U5V5 →
Q9ZW16	—	0.976	Q9ZW16 →
Q9GKX2	—	0.976	Q9GKX2 →
Q8RX32	—	0.976	Q8RX32 →
W6QKQ9	—	0.976	W6QKQ9 →
O80713	—	0.975	O80713 →
O49332	—	0.975	O49332 →
P9WGQ7	—	0.975	P9WGQ7 →
Q8SPU8	—	0.975	Q8SPU8 →
A0A1C9II22	—	0.975	A0A1C9II22 →
K4N0V2	—	0.975	K4N0V2 →
A0A6S6QNE4	—	0.975	A0A6S6QNE4 →
Q920N9	—	0.974	Q920N9 →
A0A8F5XX49	—	0.974	A0A8F5XX49 →
Q9ZW18	—	0.974	Q9ZW18 →